PARP14 was also inhibited in cellular context in a dose-dependent manner in CFPAC-1 (ductal pancreatic adenocarcinoma cells); PARP14 engagement was also confirmed in in vivo experiments by treating C57BL/6 mice with oral doses of 300 and 500 mg/kg of compound for 7 days, without observing body weight loss. The gene discussed is PARP14; the disease is pancreatic adenocarcinoma.